I.V. Bisphosphonate NCD Obviated By FDA Review And Cancer Uses, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis – manufacturer of Aredia, Reclast and Zometa – argues against opening a Medicare Part B national coverage determination for intravenous bisphosphonates.